LEXINGTON, Mass., April 23, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, have been accepted
LEXINGTON, Mass. , Feb. 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, has been accepted
LEXINGTON, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement with a leading
LEXINGTON, Mass. , Jan. 13, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it has entered into a definitive purchase agreement to raise
LEXINGTON, MA -- (Marketwired) -- 09/09/16 -- Aldeyra Therapeutics, Inc. ( NASDAQ : ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will host a Research and Development Day to discuss the company's
LEXINGTON, Mass. , Sept. 27, 2017 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity today announced that it will host
LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it will host a Research Day to
LEXINGTON, Mass. , Feb. 27, 2018 /PRNewswire/ -- Aldeyra Therapeutics , Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has entered into a collaborative
LEXINGTON, MA -- (Marketwired) -- 01/25/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Noninfectious Anterior Uveitis: Enrollment of first-ever vehicle-controlled Phase 3 clinical trial is expected to begin in the second quarter of 2017. Sjögren-Larsson Syndrome: Enrollment of first-ever Phase 3